GoldenGolden
Advanced Search
Nanotherapeutics

Nanotherapeutics

The field of nanotherapeutics is the application of nanotechnology to medicine and drug development.

Edit ID  10284947 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 22 Mar, 2019
Edits made to:
Article (+10/-10 characters)
Article

The first marketed nanocrystal drug was Rapamune, an immunosuppressant introduced by Wyeth Pharmaceuticals (Madison, NJ) in 2000. The previous form of the drug, known as Sirolimus (SRL) was poorly soluble and Rapamune, formulated using pearl mill technology increased bioavailability of the oral form of SRL by 21%. Emend launched by Merck (Winehouse Station, NJ) in 2003 was formulated from AprepitantAprepitant, a poorly water soluble anti-emetic medication. Triglide initially produced by Skypharma in 2005 and later marketed by Sciele Pharma Inc. (Altanta, GA), is a nanocrystal product derived from fenofibrate to treat hypercholestremia showed improved bioavailability and adhesiveness to the gut wall.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.